UBC researchers awarded more than $6.5 million from Brain Canada to advance neuroscience research Français
VANCOUVER, BC, June 13, 2025 /CNW/ - UBC Faculty of Medicine researchers have been awarded more than $6.5 million from Brain Canada's Platform Support Grants program to support two pioneering neuroscience research platforms. The funding will help accelerate discovery and foster open science, positioning Canada at the forefront of global brain and spine health innovation.
The two newly funded platforms are:
International Spinal Cord Injury Biobank (ISCIB): Promoting Global Spinal Cord Injury Research Through Human Biobanking, led by Dr. Brian Kwon, which will expand access to vital human biological samples for spinal cord injury research, enabling researchers worldwide to advance treatments and improve outcomes for patients.
Total Grant Awarded: $1,866,750
The University of British Columbia Genes, Cells and Circuits (UBC-GC2) Platform for Next-Generation Multiscale Brain Research, led by Dr. Mark Cembrowski, which will integrate state-of-the-art technologies to map brain function and connectivity from molecules to entire circuits, unlocking insights into complex brain disorders.
Total Grant Awarded: $4,845,000
"This platform represents a critical step toward advancing spinal cord injury research globally," said Dr. Brian Kwon, a Professor in the Department of Orthopaedics and the Director of ICORD. "By providing access to high-quality human biosamples, we're enabling researchers worldwide to develop and test new treatments that could dramatically improve quality of life for patients."
"With the UBC-GC2 platform, we're bridging the gap between molecular biology and systems neuroscience," said Dr. Mark Cembrowski, an Associate Professor in the Department of Cellular and Physiological Sciences. "By integrating cutting-edge technologies, we'll be able to study brain function at an unprecedented scale and resolution. This will not only advance our understanding of brain disorders but also open new avenues for treatments."
These platforms exemplify UBC's commitment to advancing neuroscience and fostering collaboration within and beyond Canada's borders.
"The UBC neuroscience community is grateful for Brain Canada's continued support," said Dr. Lynn Raymond, Co-Director of the Djavad Mowafaghian Centre for Brain Health at UBC. "These investments will strengthen our capacity to deliver world-class research and transform brain health for people across the lifespan."
Viviane Poupon, President and CEO of Brain Canada, emphasized the importance of these initiatives: "By supporting these cutting-edge platforms, Brain Canada is building the infrastructure that will accelerate brain and spinal cord research and foster open science collaboration. We're proud to partner with UBC to drive innovations that will impact millions of lives."
These two platforms are part of Brain Canada's broader Platform Support Grants (PSG) initiative, which has already invested in numerous projects across Canada to empower researchers with shared tools, data resources, and collaborative opportunities. The full list of funded platforms will be unveiled later this month.
Brain Canada is contributing over $18 million in this year's PSG program through the Canada Brain Research Fund (CBRF), funded by Health Canada, as well as matching donations from sponsors for a total investment of $36.8 million. By enabling access to cutting-edge tools and specialized skills beyond the reach of individual researchers, the PSG program plays a vital role in strengthening the research landscape.
"Research and innovation are essential to unlocking new treatments, improving recovery, and enhancing quality of life for people affected by brain health issues and injuries," said the Honourable Marjorie Michel, Minister of Health. "Through the Canada Brain Research Fund, the Government of Canada is very pleased to support these new neuroscience research platforms, which bring together experts from different fields, integrate cutting-edge technologies and focus on improving patient outcomes."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 hours ago
- Globe and Mail
Making their mark
In every corner of the country, in labs, hospitals and universities, a new generation of Canadians is making small but mighty advances in health, science and medicine. They are in the early stages of their promising careers. And yet, they are already deepening our understanding of diseases, from Type 1 diabetes to Alzheimer's and epilepsy – and finding new ways to help Canadians and people around the world. As well, they are making strides in learning how early-life exposures shape long-term outcomes and developing new methods for performing brain surgery on cancer patients. Canada has many early-career researchers making their mark. The Globe and Mail set out to profile five of them. The neuron was first identified in the late 1800s, but more than a century would pass before Canadian scientists found the 'ovoid,' cells nestled deep inside the brain that help us store memories of new objects so they can be recognized down the road. The discovery of this highly specialized neuron unlocks insights into how memory works, while cracking open new research pathways for better understanding – and potentially treating – neurological conditions like Alzheimer's disease. It was a breakthrough made with powerful genetic tools and tiny DIY microscopes strapped to the heads of genetically engineered mice. But the enterprising scientist who first peered into their brains in 2020 and catalyzed the discovery was a PhD student at the University of British Columbia named Adrienne Kinman. 'This is a big discovery for what we call foundational neuroscience, or just understanding how the brain works on a day-to-day level,' says Mark Cembrowski, an associate professor in the department of cellular and physiological sciences at UBC and Ms. Kinman's PhD supervisor. Growing up in Abbotsford, B.C., Ms. Kinman was a keen student and self-described 'sampler' of extracurricular interests. 'I did absolutely everything for, like, a hot second,' laughs Ms. Kinman, who is now 30. She brought her sampling tendencies to McGill University, where she enrolled as an arts student in 2013 but wound up studying psychology, molecular biology and behavioural science. She got hooked on science while working a part-time research job and started seeking out new topics to explore – everything from Alzheimer's research to studying autism with mouse models. While contemplating graduate school, she reached out to Dr. Cembrowski after he tweeted about hiring for his new lab, investigating learning and memory in the brain. 'Within five minutes of the call, I knew she was the one we had to bring into the lab,' he says. Dr. Cembrowski's earlier work had pointed toward a tiny and mysterious cluster of cells in the subiculum region of the hippocampus, which governs memory and learning. He was eager to study them in a line of genetically modified mice using a miniaturized microscope that allows brain activity to be observed in real time – a tool he didn't have at the time. He tapped Ms. Kinman. 'I needed a hero,' he says. Using soldering skills learned from YouTube and open-source plans, Ms. Kinman taught herself to build these 'one-photon fluorescence miniscopes,' which she then strapped onto the heads of these mice, 'like a tiny top hat.' She watched as these intriguing brain cells lit up whenever the mouse interacted with a novel object – say, a tiny orange pylon. But as the pylon grew familiar, the cells began to fade, never to light up again when confronted by the same object. 'It was our 'holy smokes' moment,' Dr. Cembrowski recalls. 'We were like, this is something special that nobody knows about.' More lab mates were recruited to the research effort, with Ms. Kinman at the helm. Using a variety of cutting-edge techniques, including a method that uses light to turn cells on and off, they demonstrated the existence and function of the ovoid cell – and refuted a decades-old belief that the subiculum only has one type of neuron performing a wide array of tasks. Their findings were published this February in the journal Nature Communications, with Ms. Kinman as lead author – an impressive accomplishment for someone so early in her career. Dr. Cembrowski says his lab has since done research to show that ovoid cells also exist in human brains. Ms. Kinman believes these cells have something to teach us about neurological conditions such as Alzheimer's, autism or epilepsy – potentially leading to novel therapies down the road. 'I can't wait to see how this turns out.' - Jennifer Yang Growing up in Albania, one of Kozeta Miliku's favourite games was playing doctor, with her cousin enlisted for the role of pharmacist. Using empty pill bottles donated by a neighbour – an actual pharmacist – they passed many hours in this imaginary play. 'I always had the dream of becoming a doctor,' she says. 'I wanted to save people.' She later got into medical school, but toward the end of her physician training it dawned on her that many patients suffer from diseases that can be prevented. 'I often saw the downstream effects of chronic disease but what I became increasingly interested in was the upstream factors,' she says. 'I wanted to understand how early exposures, even those before birth, can influence lifelong health.' Dr. Miliku pivoted toward clinical epidemiology, and today the 37-year-old mother of one is an assistant professor with the department of nutritional sciences at the University of Toronto, where she runs a lab that investigates the factors that shape lifelong health. Her research has already revealed alarming insights, including that Canadian three-year-olds were getting nearly half of their daily calories from ultraprocessed foods, putting them at higher risk of obesity. This year, she published a study showing that children born to fathers who are obese or overweight around the time of conception are more likely to develop obesity themselves. Dr. Miliku's research is largely powered by data from the CHILD cohort study – the research initiative that drew her to Canada in the first place, and for which she now serves as clinical science officer. Since 2009, CHILD researchers have been tracking thousands of children from across Canada starting at birth, collecting health information and physical samples at different ages – everything from blood or diaper poop to the dust inside a baby's house. The result is a powerful and ever-expanding dataset that's already produced more than 200 peer-reviewed papers on everything from the infant gut microbiome to risk factors for asthma. 'It's a world-renowned research initiative,' Dr. Miliku says. 'It's an amazing study, one of the best and the largest cohorts we have in Canada.' After receiving her medical degree from the Medical University of Tirana in 2013, Dr. Miliku moved to the Netherlands to pursue her masters and PhD at Erasmus University Medical Center, where she worked on Generation R, another prospective cohort study. She became fascinated with breastmilk, especially its beneficial impact on kidney development. 'I couldn't sleep,' she says. 'I was like, what is in breastmilk that is driving these important health outcomes?' At some point, she decided to look for breastmilk experts. The first name she came across was Meghan Azad, a University of Manitoba professor and deputy director of CHILD. Dr. Miliku fired off an e-mail to Dr. Azad and they connected the next day. 'She said, 'Do you want to work as a postdoctoral fellow in my lab?'' Dr. Miliku recalls, chuckling. 'It happened so quickly.' After moving to Manitoba in 2017, Dr. Miliku worked with Dr. Azad to continue studying breastmilk, investigating the components that might be protective against childhood asthma or allergies. Three years later, she was recruited to McMaster University, home to CHILD's national collaborating centre, and appointed the study's clinical science officer. In this role, Dr. Miliku designs study protocols for the child visits, consulting with CHILD's massive expert network to determine what data to collect, as well as the research questions to explore. Dr. Miliku says CHILD researchers want to empower study participants – something she credits for the study's high retention rate, even throughout the early pandemic. Last summer, CHILD asked some of its teenaged participants what they wanted researchers to focus on. 'They said mental health, which was not a key outcome in the CHILD study originally,' Dr. Miliku says. 'But now we're really pushing into mental health.' Dr. Miliku has a long career ahead of her but she hopes that by the time she reaches the other end of it, she will have accomplished her childhood goal of saving people – by stopping diseases before they start. 'My goal is to improve the health and well-being of Canadian families, through the prevention path at the early stages of life,' she says. 'Before the problems develop.' - Jennifer Yang Grant Bruno, a member of Samson Cree Nation in Alberta, has a singular goal - working to establish a global network of Indigenous autism researchers. Prof. Bruno, 38, completed his PhD in 2024 and has worked as an assistant professor in the University of Alberta's pediatrics department for nine months. He brings a personal connection to this work: Two of his five children have autism; both present differently. He said his eldest son is completely verbal, can attend high school and interacts with his peers. His younger son struggled to find the right words for several years and wasn't using full sentences until about two years ago. 'I think that it's important for people to understand that autism is very complex,' Prof. Bruno said. Much of what people know about autism is influenced by a medical model that often involves the use of negative language, he added. But he said that his cultural teachings see it in a very different way. 'We don't have a word that directly translates as autism; we don't even have a word for disability,' he said. 'And I think that's really beautiful, because we're not looking for differences in people. We're celebrating those, and so elders have often told me that these children, they're sacred children.' Prof. Bruno said he brings these teachings to the families that he works with. He is passionate about offering supports, which motivated him to create a program called the Indigenous Caregiving Collective. The goal of the project is to build a network of organizations, Indigenous elders, researchers and health care providers that can share knowledge to improve policies for caregivers who may encounter challenges, such as delayed assessments and treatment. While he was conducting research across many First Nations for his doctorate, caregivers shared that they can feel isolated and like no one understands them. Often, he said, families have questions or simply want to connect. 'I felt like starting the Indigenous Caregiving Collective was a really good step, at least to start to support and connect with caregivers right across Canada,' Prof. Bruno said. Prof. Bruno is hopeful neurodevelopmental differences can be supported and embraced. His perspective is rooted in a cultural teaching: children choose us. (His relationship with his sons was captured in a documentary called The Gift of Being Different.) 'I think that's really important, because that allows me just to practise unconditional acceptance with them,' he said. - Kristy Kirkup Yi-Chun Chen, who started working as an assistant professor of anatomy, physiology and pharmacology at the University of Saskatchewan in the past year, has focused her research on the body's endocrine system – and specifically its relationship with diabetes. The endocrine system uses hormones as messengers to tell organs and tissue what to do in different situations. After humans eat food, blood glucose goes up and the body makes and releases insulin. For a patient with diabetes, the body doesn't respond to insulin well, or they don't make enough of it. And while Canadian scientists have already made tremendous progress in diabetes research, including discovering insulin more than 100 years ago in Toronto, researchers want to learn more about when, and how much of, the hormone is needed. Dr. Chen is also looking at preventative strategies. 'Our research focuses on studying how insulin is produced in a specialized cell called beta cells, in the pancreas.' If she can discover how insulin functions in these cells, it could help unlock future therapies for stopping diabetes from developing in the first place. At 39, Dr. Chen also is excited to see what researchers even younger than herself will uncover in her field – and she's guiding students who will be the next wave of researchers. 'The young scientists, they are actually the future of Canada,' she said. 'We're hoping to support them and mentor them and they are going to do great things.' - Kristy Kirkup Even as a young boy growing up in Scarborough, Ont., Dilakshan Srikanthan was keenly interested in the brain – both because of its pre-eminence and its vulnerability as the body's control centre. He knew that a neurological condition had affected his grandmother in Sri Lanka, a personal experience that eventually steered him toward a degree in neuroscience at the University of Toronto, and then onto graduate work on brain tumours. But it was a timely bit of made-in-Canada wisdom that set him on his current course. 'Skate to where you think the puck is going to be, not to where it's already been,' he was told by James Rutka, a renowned brain surgeon at Toronto's Hospital for Sick Children who was his master's degree supervisor and mentor. For Mr. Srikanthan, that has meant utilizing artificial intelligence to help turn an experimental technology into a reliable tool for brain tumour surgery. The project is one he is now pursuing in a combined PhD/MD program at Queen's University in Kingston under the guidance of computer scientist Parvin Mousavi and surgeon-researchers Teresa Purzner and John Rudan. As a rule, any form of cancer surgery is a high-wire act in which the goal is to remove the disease while doing as little harm as possible to the surrounding tissue. And nowhere are the stakes higher than in the brain. 'Surgeons want to draw this fine balance between how much do I take and how much do I leave behind,' Mr. Srikanthan said. 'Do I want to cause neurological deficits for the sake of getting all the cancer?' Answering that question requires a detailed understanding of the area being operated on and a tool that can allow the surgeon to discriminate between healthy and cancerous tissue with high precision. A promising new technology in this area is the iKnife, a surgical instrument that identifies the biochemical composition of tissue that it comes in contact with in near real time. First devised by Zoltan Takats, a chemist and professor at Imperial College London, the technology consists of a needle-like implement that burns away cells and vacuums up the resulting smoke, which is sent to a mass spectrometer to read its chemical signature. Cancer cells have chemical differences that can be used to distinguish them from healthy cells. When brain tissue is vapourized by an iKnife, those difference should make it possible to identify where a tumour begins and ends while the surgery is in progress. The same technology has been applied to various kinds of cancers but it is not a standard tool for brain surgery. Now Mr. Srikanthan is using artificial intelligence to train the iKnife to do just that. The work involves developing computer algorithms and using deep-learning techniques to teach the computer to reliably identify tissue types based on the constituents found in tiny wisps of smoke. It is a new skill that he has added to his medical and neurological training, and a glimpse at what the future of surgery could offer. 'The possibilities are limitless,' said Mr. Srikanthan, who received a prestigious Vanier scholarship in 2023 to support his PhD research. The ultimate goal, he said, is to accelerate the translation of such AI-driven experimental methods to the point where they can be of benefit to patients. 'I know that if I saw that future as a clinician I'd want to be able to do something about it,' he said. 'So I'm really focused on learning the skill set as a scientist that I can apply to whatever problem I see.' - Ivan Semeniuk
Cision Canada
5 hours ago
- Cision Canada
Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS
NEW YORK, /CNW/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with manufacturing and process development work in preparation for clinical trials of KLTO-202, its investigational gene therapy for amyotrophic lateral sclerosis (ALS). A unique RNA splice variant of the human gene called alpha-Klotho has been licensed by the Company from the Autonomous University of Barcelona ("UAB") including patents, patent applications, research, knowhow and other intellectual properties for use in the development of advanced gene and gene-engineered cell therapies. The human alpha-Klotho gene is located in cells found throughout the human body. It is a five exon gene that produces two protein isoforms: a full-length protein found mainly in cells of the kidney called membrane-bound Klotho (or m-KL), which controls phosphate homeostasis, and a much smaller protein isoform called secreted alpha-Klotho (or s-KL). The s-KL RNA splice variant is found mainly in the brain and spinal cord neurons; the variant protein is neuroprotective by minimizing both oxidative stress and neuroinflammation. Animal studies supported by the Company over the past two years in mouse and non-human primate models of rapid aging, in models of human Alzheimer's disease, and in models of ALS have shown that over-expression and amplification of the tissue levels of s-KL using a gene therapy approach result in highly favorable therapeutic outcomes in every model tested. These results have been published in peer-reviewed scientific journals and now support the transition of KLTO-202 into the clinical development stage. The Company expects that it will take approximately eight months to complete process development and manufacturing of KLTO-202, and about four to six months to conduct meetings with FDA, complete all FDA-mandated animal safety studies, file an investigational new drug application (IND), train and prepare clinical sites where the Phase I/II studies can be conducted, and then begin the single-dose gene therapy studies in ALS patients by the third quarter of next year. The Company will work with contract research organizations (CROs) to facilitate all activities including manufacturing and clinical trials without the need to hire several dozen staff members, which would significantly increase our operating overhead. Dr. Joseph Sinkule, the Company's CEO and founder commented: "With our recent fundraising success, we're moving forward with manufacturing the s-KL transgene DNA for KLTO-202. We've identified a more efficient method of producing the AAV vector to deliver the s-KL gene directly to motor neurons—the cells most affected by ALS. Our goal is to increase local s-KL protein levels to protect these neurons from the damage that leads to voluntary and involuntary muscle paralysis and ultimately death." ALS typically progresses rapidly, with most patients losing mobility, respiratory function, and life within just 2–3 years of diagnosis. About Klotho Neurosciences, Inc. Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The Company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The Company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization. Investor Contact and Corporate Communications - Jeffrey LeBlanc, CFO [email protected] Forward-Looking Statements: This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
Cision Canada
13 hours ago
- Cision Canada
ESHRE 41st Annual Meeting: Older paternal age linked to higher miscarriage risk and lower live birth rates in donor egg IVF cycles
A new international study presented today at the 41 st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) reveals that IVF cycles involving male partners over the age of 45 carry significantly increased miscarriage risks and lower live birth rates – even when young donor eggs are used. PARIS, June 29, 2025 /CNW/ -- By isolating paternal age from female reproductive factors through the exclusive use of donor eggs from young women, the study provides robust evidence that male age plays a critical role in reproductive success, challenging the common assumption that sperm age has little impact once fertilisation occurs. The retrospective study analysed 1,712 first oocyte donation cycles conducted between 2019 and 2023 across six IVF centres in Italy and Spain. All cycles used fresh donor oocytes and frozen sperm from male partners, with only the first single blastocyst transfer included. Female recipients had a mean age of 43.3 years. Participants were divided into two groups: men aged 45 or younger (n=1,066) and those over 45 (n=646). While fertilisation rates and embryo development were comparable between groups, significant differences emerged in clinical outcomes. Miscarriage rates were notably higher among couples where the male partner was over 45, reaching 23.8% compared to 16.3% in the younger paternal age group. Similarly, live birth rates were significantly lower in the older paternal age group, at 35.1% versus 41% for men aged 45 or younger. Discussing the findings, Dr. Maria Cristina Guglielmo, Embryologist at Eugin Italy, said, "Traditionally, maternal age has been the central focus in reproductive medicine, but our results show that the age of the male partner also plays a crucial and independent role. Even when using eggs from young, healthy donors and transferring only a single, high-quality embryo, we observed poorer outcomes in men over 45." She also emphasised the importance of examining how paternal age affects the health of offspring. "There is growing evidence linking advanced paternal age to an increased risk of neurodevelopment disorders in children. Our future work will investigate the long-term health and developmental outcomes of children conceived through donor egg cycles with older fathers, where maternal factors are minimised, to isolate paternal effects more clearly." The study abstract will be published today in Human Reproduction, one of the world's leading reproductive medicine journals.
